Concord, MA – According to filings with the U.S. Securities and Exchange Commission, Beta Bionics is raising $57,049,776.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Ed Damiano played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Beta Bionics
Beta Bionics is proud to be a Massachusetts public benefit corporation. We believe we are one of the first, if not the first medical device company to be doing business as a benefit corporation, and were fairly certain that Beta Bionics is the first company to do so in the diabetes space. We believe our status as a public benefit corporation is going to make all the difference in the way we do business and, ultimately, will result in a healthier and happier T1D community. We know that if we pursue our public benefit mission, everybody wins. So far, our investors love our structure. If they don’t, we don’t want them as investors, its as simple as that. Wed love to hear your thoughts about our model and public mission.

To learn more about Beta Bionics, visit https://www.betabionics.com/

Contact:
Ed Damiano, Chief Executive Officer
909-800-3351
edamiano@betabionics.org

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved